CLINICAL TRIAL

The Neurobiological Effect of 5-HT2AR Modulation

The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin). Magnetic resonance imaging (MRI) and positron emission tomography (PET) will be used as neuroimaging tools. This project applies an experimental medicine strategy coupled with human functional and molecular neuroimaging to elucidate the effects of 5-HT2A receptor (5-HT2AR) modulation on brain function and mood in healthy individuals. We compare psilocybin (5-HT2AR agonist) and ketanserin (5-HT2AR antagonist) effects on brain function to identify neural mechanisms mediating the clinical effects of psilocybin and, more broadly, to establish this comparative strategy as a pathway for delineating pharmacological effects on the brain in humans.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2024-12-15
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Gitte Moos Knudsen

Watch author

Topics and keywords

psilocybin Brain Imaging Mechanism of Action Receptor Pharmacology Aging Healthy Volunteers Other Basic Science Psilocybine Psilocybin Ketanserin Ketensin RECRUITING

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Acute psilocin increased cortical activity in ratFrontiers in Neuroscience · 2026-02-03 Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic painNature Neuroscience · 2025-10-01 Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionClinicalTrials.gov · 2026-03-29 Explainable AI framework for psilocybin depression treatment optimizationFrontiers in Computer Science · 2026-03-15 A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy VolunteersClinicalTrials.gov · 2026-02-12 PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERSJournal of medical & health sciences review. · 2025-03-10 Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility studyPhilosophical Transactions of the Royal Society B Biological Sciences · 2024-10-20 Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitaloprambioRxiv · 2026-06-25